Zai Lab
Zai Lab Limited, commonly referred to as Zai Lab, is a prominent biopharmaceutical company headquartered in China. Founded in 2014, the company has rapidly established itself as a leader in the development of innovative therapies, focusing primarily on oncology, autoimmune diseases, and infectious diseases. With a strong operational presence in both China and the United States, Zai Lab is committed to addressing unmet medical needs through its robust pipeline of novel drug candidates. The company’s core offerings include a range of proprietary and partnered products, distinguished by their unique mechanisms of action and potential to improve patient outcomes. Zai Lab has achieved significant milestones, including successful collaborations with global pharmaceutical leaders and the launch of several key therapies in the Chinese market. Recognised for its commitment to innovation, Zai Lab continues to strengthen its position in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Zai Lab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zai Lab's score of 28 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zai Lab's reported carbon emissions
In 2022, Zai Lab reported total carbon emissions of approximately 73,481,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 19,000 kg CO2e, while Scope 2 emissions amounted to approximately 3,951,000 kg CO2e. The company also disclosed significant Scope 3 emissions, including 51,051,000 kg CO2e from purchased goods and services, 8,786,000 kg CO2e from capital goods, and 6,542,000 kg CO2e from business travel. Zai Lab has committed to near-term climate targets, although it has not set a net-zero target. The company is actively engaged in climate initiatives within the pharmaceuticals, biotechnology, and life sciences sector, with its headquarters located in China. As of July 2023, Zai Lab's near-term target status is classified as "Committed," indicating a proactive approach to addressing its carbon footprint. The emissions data is sourced directly from Zai Lab Limited, with no cascading from a parent organization. The company continues to monitor and report its emissions, aiming for transparency and accountability in its climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 28,400 | 00,000 |
| Scope 2 | 3,536,600 | 0,000,000 |
| Scope 3 | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zai Lab is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
